NASDAQ:HALO
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc.'s revenue grew 37.6% in fiscal 2025 to $1.4B while operating margin fell to 33.6%. Free cash flow was $644.6M, 46.2% of revenue, and the diluted share count fell 4.3%.Summary generated from Halozyme Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.4B
Revenue growth+37.6%
Revenue, 5-yr CAGR+39.2%
Gross margin83.6%
Operating margin33.6%
Net margin22.7%
ROIC16.7%
Return on equity153.6%
Debt / equity43.89
Free cash flow$644.6M
FCF margin46.2%
Share count change−4.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 443 | 660 | 829 | 1,015 | 1,397 |
| Operating income | 276 | 268 | 338 | 551 | 469 |
| Net income | 403 | 202 | 282 | 444 | 317 |
| Free cash flow | 298 | 235 | 373 | 468 | 645 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KDirector or officer change
Sep 30, 2026 - 8-KEntry into a material agreement
Sep 22, 2026 - 8-KOther events
Sep 18, 2026 - 8-KOther events
Sep 16, 2026 - 8-KDirector or officer change
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026